HDAC inhibitors in cancer therapy

Ganesan, A. ORCID: https://orcid.org/0000-0003-4862-7999 (2020) HDAC inhibitors in cancer therapy. In: Histone Modifications in Therapy. Elsevier, pp. 19-49. ISBN 9780128164228

Full text not available from this repository. (Request a copy)

Abstract

Reversible lysine acetylation is a major posttranslational modification in histones and nonhistone proteins. Modulation of this process is an important target for drug discovery, most successfully through the inhibition of zinc-dependent histone deacetylases (HDACs). There are five HDAC inhibitors approved for the treatment of hematological cancers and more than 20 others in clinical development. This chapter reviews the current state of the art of HDAC therapy in terms of the biological functions of the enzymes, the structural classes of HDAC inhibitors, and their utility in cancer therapy based on the data from recent clinical trials.

Item Type: Book Section
Uncontrolled Keywords: cancer chemotherapy,drug discovery,enzyme inhibitors,epigenetics,histone deacetylases,metal-binding drugs,posttranslational modifications,biochemistry, genetics and molecular biology(all),sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/1300
Faculty \ School: Faculty of Science > School of Pharmacy
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 12 Sep 2020 00:34
Last Modified: 01 Oct 2022 08:32
URI: https://ueaeprints.uea.ac.uk/id/eprint/76853
DOI: 10.1016/B978-0-12-816422-8.00002-7

Actions (login required)

View Item View Item